Meeting the COVID challenge: Optimizing vCD34 + in cryopreserved HPC samples for implementation of an external QA ProgramCOVID 문제 해결: 외부 QA 프로그램 구현을 위해 냉동보존된 HPC 샘플에서 vCD34 + 최적화Multicenter Study Published on 2022-04-012022-09-11 Journal: Cytotherapy [Category] 바이오마커, [키워드] Allogeneic Analysis approach CD34 Cell Combination condition COVID COVID-19 pandemic CRS cryopreserved reference sample cytometric dispatch distance distribution dry ice Enumeration evaluate exclusion External external quality assurance Flow followed by harmonization hematopoietic progenitor cell implementation interlaboratory comparison liquid nitrogen meeting multicenter multicenter study National nitrogen Pandemics platform proficiency testing Program Quality Quality assurance reproducibility specificity transplantation viability viable CD34(+) HPC enumeration. was performed [DOI] 10.1016/j.jcyt.2021.10.009 PMC 바로가기 [Article Type] Multicenter Study
Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation동종 조혈 세포 이식 후 환자에서 SARS-CoV-2 백신 접종에 대한 항체 반응Article Published on 2022-04-012022-09-11 Journal: Transplantation and cellular therapy [Category] COVID19(2023년), SARS, 치료법, [키워드] age Allogeneic Allogeneic hematopoietic cell transplantation Analysis antibody antibody levels Antibody Response Antibody titer Antibody titers approved BNT162b2 Cell cell transplantation chronic GVHD Cohort conditioning regimen conducted Critical disease domain Efficacy examined Factor Graft-versus-host disease group GVHD had no healthy control healthy controls healthy volunteers hematopoietic Hematopoietic cell transplantation highest homogenous humoral immune response IgA IgG IgM immune response immune responses Immunocompromised patients Immunosuppression information intensity Moderna mRNA mRNA vaccine mRNA vaccines mRNA-1273 nucleocapsid protein pandemic Patient physician reactivity receiving Receptor-binding domain recipient recipients regimen response revaccination S1 and S2 SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 antigens SARS-CoV-2 pandemic SARS-CoV-2 vaccination second dose significantly lower single center spike glycoprotein stratified subunit Switzerland the SARS-CoV-2 the vaccine transplantation Treatment underlying disease vaccination Vaccine waned was performed [DOI] 10.1016/j.jtct.2022.01.019 PMC 바로가기 [Article Type] Article
Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patientsClinical Trial Published on 2022-03-082022-10-04 Journal: Blood advances [Category] SARS, 임상, [키워드] Allogeneic Analysis antibody Antibody concentrations Antigen autologous benefit binding antibody unit Cell cell transplantation Chemotherapy chimeric antigen receptor CLL Concentration COVID-19 vaccination disease HCT hematological hematology high risk High-dose identify IgG IgG4 Immunocompromised Immunoglobulin Immunosuppressant in healthy individuals leukemia lymphoma mRNA-1273 Multiple myeloma myeloid malignancies Netherland Obtaining Patient patients patients treated precluded predicted quantified recipient Registered response S1 IgG serum severe COVID-19 subunit T-cell therapy Treatment Trial vaccination Virus neutralization [DOI] 10.1182/bloodadvances.2021006917 PMC 바로가기 [Article Type] Clinical Trial
Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & IIRandomized Controlled Trial Published on 2022-03-072022-10-04 Journal: Stem Cell Research & Therapy [Category] MERS, SARS, 임상, [키워드] 1:1 acute phase reactant Adverse adverse effect adverse event Allogeneic analyzed C-reactive protein caused CD4 CD8 chest imaging clinical symptom clinical trial control group COVID-19 Cytokine storm D-dimer declined demonstrated double-blind downregulation duration of hospitalization Efficacy Enrollment evaluate events ferritin FIVE GMP hospitalized patient hypoxia immune immune system increase in inflammatory lung disease injection intravenous infusion Intubated Laboratory parameters lymphocyte Lymphocyte count lymphopenia mechanism menstrual blood Menstrual blood stromal cells Mesenchymal stromal cell modulate MSCs New treatment outcomes Oxygen level Patient patients Phase I Placebo placebo-controlled clinical trial pulmonary involvement Randomized reduction Registered Result Safety safety endpoint SARS-CoV-2 Secretome severe COVID-19 Significant significantly stromal cell suppress survival rate survivor therapy treat treated Treatment treatment group Volume [DOI] 10.1186/s13287-022-02771-w PMC 바로가기 [Article Type] Randomized Controlled Trial
Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant동종이식 후 BNT162b2 anti-SARS-CoV-2 메신저 RNA 백신 3차 접종에 대한 관심Article Published on 2022-03-012022-09-12 Journal: British Journal of Haematology [Category] MERS, SARS, 진단, [키워드] Abstract acute respiratory syndrome Allogeneic allogeneic haematopoietic stem cell transplantation anti-SARS-CoV-2 BNT162b2 Cell coronavirus disease Coronavirus disease 2019 (COVID-19) Coronavirus-2 dose interest Messenger RNA of BNT162b2 SARS-CoV-2 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA third dose Vaccine [DOI] 10.1111/bjh.17911 PMC 바로가기 [Article Type] Article
SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variantsResearch Article Published on 2022-02-142022-10-29 Journal: PLoS Pathogens [Category] COVID-19, COVID19(2023년), SARS, [키워드] alleles Allogeneic Anti-viral Antigen approach can be used Cell Complication convalescent individual Coverage COVID-19 Critical Effectiveness epitope Evidence expand functional generate healthy HLA HLA class I humans immune immune system Immunocompromised patient Immunotherapy increased risk individual leukocyte observation offer Patient phenotypic powerful tool provided recognize recognizing reduce remain unchanged Repository Research risk robust SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2-specific T cell screened selected severe complication severe COVID-19 susceptible T cell T cells T-cell T-cell Response target transfer treat Treatment Vaccines variant variants of SARS-CoV-2 viral disease viral infections virus-specific T cell while with COVID-19 [DOI] 10.1371/journal.ppat.1010339 PMC 바로가기 [Article Type] Research Article
Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individualsSARS-CoV-2에 대한 타액 IgG는 혈청 전환을 나타내며 mRNA 백신 접종 면역 저하된 개인의 혈청 중화와 상관 관계가 있습니다Article Published on 2022-02-112022-09-12 Journal: Med (New York, N.Y.) [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] acute respiratory syndrome ALF Allogeneic Analysis Anti-SARS-CoV-2 S antibody Antigen AUC Cancer CAR-T caused center CLL CLL patient comparable coronavirus correlated Council COVID-19 disease dose Elecsy entire cohort foundation group healthy control HIV Human immunodeficiency virus IgG IgG response IgG titer immunocompromised individual immunodeficiency Immunoglobulin immunosuppressants indicate individual Infection Innovation Knut leukemia Medical Research Council mRNA BNT162b2 mRNA BNT162b2 vaccine multiplex neutralizing capacity parameter participated Patient PID Positive predictive value PPV predictive power Primary Immunodeficiency primary site Prospective clinical trial reactivity receiver operating characteristic receptor Region response responses revaccination Saliva salivary SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 spike antigen Seroconversion serum Serum Neutralization solid organ transplantation SOT spike IgG Stem cell transplantation Stockholm County susceptible Swedish T cell therapy transplantation vaccination vaccine response Vaccine-induced immunity were measured [DOI] 10.1016/j.medj.2022.01.001 PMC 바로가기 [Article Type] Article
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients조혈모세포이식 환자에서 BNT162b2 mRNA 코로나19 백신의 면역원성과 안전성Article Published on 2022-02-012022-09-12 Journal: British Journal of Haematology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] 95% CI Adverse Allogeneic analyzed antibody blood sample BNT162b2 mRNA BNT162b2 mRNA vaccination BNT162b2 mRNA vaccine Cell chronic GVHD confidence interval Control control group controls COVID-19 COVID-19 vaccine disease domain effective event fraction geometric mean titre GMT GVHD haematopoietic stem cell transplantation healthcare worker healthy controls HSCT HSCT recipient HSCT recipients IgG immunogenicity Immunoglobulin immunosuppressive less Logistic regression analysis median multivariate Neutralizing Neutralizing antibodies neutralizing antibody Patient Pfizer-BioNTech RBD RBD IgG recipient Safe second vaccination significantly higher Stem cell transplantation therapy vaccination [DOI] 10.1111/bjh.17918 PMC 바로가기 [Article Type] Article
Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation동종 조혈 세포 이식 후 BNT162b2 백신에 대한 체액 혈청 반응Article Published on 2022-02-012022-09-12 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] 95% confidence interval 95%CI Allogeneic Allogeneic haematopoietic cell transplantation anti-spike antibodies BNT162b2 BNT162b2 vaccine Cell cell transplantation chronic GVHD Cohort comparable declined demonstrated disease General population Graft-versus-host disease GVHD HCT humoral humoral immune response Immunosuppression moderate Odds ratio Patient patients precautions proportion prospective cohort study quantitative measurement receiving recipient reported SARS-CoV-2 serological response seronegative seronegative patient Symptom vaccination was performed worsened [DOI] 10.1016/j.cmi.2021.10.007 PMC 바로가기 [Article Type] Article
Cytokine Storm in COVID-19: Immunopathogenesis and TherapyCOVID-19의 사이토카인 폭풍: 면역 병인 및 치료Review Published on 2022-01-182022-09-12 Journal: Medicina [Category] SARS, 진단, [키워드] administration affected Allogeneic allogeneic hematopoietic stem cell transplantation Anakinra antibody autoinflammatory disease CAR Care clinically Coagulopathy conditions coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patients Critically ill critically ill patients cytokine cytokine inhibitors Cytokine storm Cytokines death deregulated disease disease severity effective effort excessive production of cytokines glucocorticoid Glucocorticoids GM-CSF Graft Graft-versus-host disease Hematopoietic stem cell hemophagocytic lymphohistiocytosis Hope hyperinflammatory state IFN-γ IL-1 IL-10 IL-2 IL-6 immune cells immune system IP-10 jak inhibitors leading MCP-1 Methylene blue mitigate multi-organ failure Novel coronavirus novel coronavirus disease overcome pandemic Pathogenesis Patient Plasmapheresis pro-inflammatory cytokines reducing mortality secondary hemophagocytic lymphohistiocytosis secondary to Sepsis severe cases stem cell Stem cell transplantation storm syndrome T-cell tested the cytokine storm the disease therapeutic strategy therapy TNF-α to define Tocilizumab [DOI] 10.3390/medicina58020144 PMC 바로가기 [Article Type] Review